Lead
Preclinical / discovery stageRecent clinical, regulatory, research and industry developments relating to this drug.
Recursion Eyes H2 2027 Pivotal Trial for Lead Candidate After Positive Phase II FAP Data
Testosterone therapy may lead to CVD risk in postmenopausal women
Lilly’s music-loving, intense lead dealmaker knows what he wants
Donating a Kidney Could Lead to Later Pregnancy Complications
Nouscom raises $135M in Series D for lead cancer vaccine
Lead-tainted teeth reveal medieval mines’ unequal toll
The Role of P62/Nrf2/Keap1 Signaling Pathway in Lead-Induced Neurological Dysfunction.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes8
Journals, researchers & institutions
- Clinical cancer research : an official journal of the American Association for Cancer Research1
- CNS neuroscience & therapeutics1
- Scientific reports1
- Bynoe K1
- Chaudagar K1
- Drovetsky C1
- Fan X1
- Grätzel M1
- Hieromnimon HM1
- Humphry-Baker R1
- Im JH1
- Animal Resource Center1
- Department of Pathology and Laboratory Medicine1
- Guangxi Colleges and Universities Key Laboratory of Prevention and Control of Highly Prevalent Diseases1
- School of Chemical Engineering and Department of Energy Science1
- School of Public Health1
- University of Chicago1
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
- RxNorm (U.S. National Library of Medicine) — drug identity
- Europe PMC — research literature